Expression of type 5 somatostatin receptor in TSH-secreting pituitary adenomas: A possible marker for predicting long-term response to octreotide therapy

被引:45
作者
Yoshihara, Ai
Isozaki, Osamu
Hizuka, Naomi
Nozoe, Yasuko
Harada, Chie
Ono, Masami
Kawamata, Takakazu
Kubo, Osami
Hori, Tomokatsu
Takano, Kazue
机构
[1] Tokyo Womens Med Univ, Inst Clin Endocrinol, Dept Med, Shinjuku Ku, Tokyo 1628666, Japan
[2] Tokyo Womens Med Univ, Inst Clin Neurol, Dept Neurosurg, Shinjuku Ku, Tokyo 1628666, Japan
关键词
TSHoma; somatostatin receptor; octreotide;
D O I
10.1507/endocrj.K06-133
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In TSH-secreting pituitary adenomas (TSHoma), octreotide (OCT) therapy reduces tumor size and TSH secretion in some cases but not in others. As OCT acts through various types of somatostatin receptors (SSTRs), the different responses of TSHoma to OCT might be explained by the differences of SSTR expression. We therefore studied the expression of subtype-specific SSTR mRNA transcripts in tumor tissues by RT-PCR. Type 2 (SSTR2) mRNA transcripts were detected in all 8 tumors but those of SSTR3 and SSTR5 were demonstrated only in 5 of them. Serum TSH levels were decreased by OCT administration test in all patients but OCT therapy was effective in two patients out of three. SSTR5 mRNA was detected in two tumors from the responder, but not in one tumor that was resistant to OCT. These observations suggest that the temporal decrease of TSH by OCT may be mediated by SSTR2, and that the long term response to OCT therapy may be related with the expression of SSTR5. Therefore, the expression of SSTR5 in TSHoma may be a useful marker for predicting the outcome of the therapy, but further studies with larger numbers of patients are necessary.
引用
收藏
页码:133 / 138
页数:6
相关论文
共 33 条
[1]   Genome comparisons highlight similarity and diversity within the eukaryotic kingdoms [J].
Ball, CA ;
Cherry, JM .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2001, 5 (01) :86-89
[2]   Impact of gsp oncogene on the expression of genes coding for Gsα, Pit-1, Gi2α, and somatostatin receptor 2 in human somatotroph adenomas:: Involvement in octreotide sensitivity [J].
Barlier, A ;
Pellegrini-Bouiller, I ;
Gunz, G ;
Zamora, AJ ;
Jaquet, P ;
Enjalbert, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (08) :2759-2765
[3]   THYROTROPIN-SECRETING PITUITARY-ADENOMAS - REPORT OF 7 CASES [J].
BECKERS, A ;
ABS, R ;
MAHLER, C ;
VANDALEM, JL ;
PIRENS, G ;
HENNEN, G ;
STEVENAERT, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 72 (02) :477-483
[4]   Thyrotropin-secreting pituitary tumors [J].
BeckPeccoz, P ;
BruckerDavis, F ;
Persani, L ;
Smallridge, RC ;
Weintraub, BD .
ENDOCRINE REVIEWS, 1996, 17 (06) :610-638
[5]   TREATMENT OF HYPERTHYROIDISM DUE TO INAPPROPRIATE SECRETION OF THYROTROPIN WITH THE SOMATOSTATIN ANALOG SMS 201-995 [J].
BECKPECCOZ, P ;
MARIOTTI, S ;
GUILLAUSSEAU, PJ ;
MEDRI, G ;
PISCITELLI, G ;
BERTOLI, A ;
BARBARINO, A ;
RONDENA, M ;
CHANSON, P ;
PINCHERA, A ;
FAGLIA, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1989, 68 (01) :208-214
[6]   SOMATOSTATIN RECEPTORS ON THYROTROPIN-SECRETING PITUITARY-ADENOMAS - COMPARISON WITH THE INHIBITORY EFFECTS OF OCTREOTIDE UPON INVIVO AND INVITRO HORMONAL SECRETIONS [J].
BERTHERAT, J ;
BRUE, T ;
ENJALBERT, A ;
GUNZ, G ;
RASOLONJANAHARY, R ;
WARNET, A ;
JAQUET, P ;
EPELBAUM, J .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 75 (02) :540-546
[7]   Efficacy of the long-acting octreotide formulation (Octreotide-Lar) in patients with thyrotropin-secreting pituitary adenomas [J].
Caron, P ;
Arlot, S ;
Bauters, C ;
Chanson, P ;
Kuhn, JM ;
Pugeat, M ;
Marechaud, R ;
Teutsch, C ;
Vidal, E ;
Sassano, P .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (06) :2849-2853
[8]   OCTREOTIDE THERAPY FOR THYROID-STIMULATING HORMONE-SECRETING PITUITARY-ADENOMAS - A FOLLOW-UP OF 52 PATIENTS [J].
CHANSON, P ;
WEINTRAUB, BD ;
HARRIS, AG .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (03) :236-240
[9]   TREATMENT OF THYROID-STIMULATING HORMONE-SECRETING ADENOMAS WITH OCTREOTIDE [J].
CHANSON, P ;
WARNET, A .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1992, 41 (09) :62-65
[10]   RESPONSE OF THYROTROPIN-SECRETING PITUITARY-ADENOMAS TO A LONG-ACTING SOMATOSTATIN ANALOG [J].
COMI, RJ ;
GESUNDHEIT, N ;
MURRAY, L ;
GORDEN, P ;
WEINTRAUB, BD .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (01) :12-17